Flow cytometric method transfer: Recommendations for best practice
- 18 November 2020
- journal article
- review article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 100 (1) , 52-62
Abstract
As with many aspects of the validation and monitoring of flow cytometric methods, the method transfer processes and acceptance criteria described for other technologies are not fully applicable. This is due to the complexity of the highly configurable instrumentation, the complexity of cellular measurands, the lack of qualified reference materials for most assays, and limited specimen stability. There are multiple reasons for initiating a method transfer, multiple regulatory settings, and multiple context of use. All of these factors influence the specific requirements for the method transfer. This recommendation paper describes the considerations and best practices for the transfer of flow cytometric methods and provides individual case studies as examples. In addition, the manuscript emphasizes the importance of appropriately conducting a method transfer on data reliability.Keywords
This publication has 25 references indexed in Scilit:
- Quality assessment program forEuroFlow protocols: Summary results of four‐year (2010–2013) quality assurance roundsCytometry Part A, 2014
- Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL studyCytometry Part A, 2013
- Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteriaCytometry Part B: Clinical Cytometry, 2013
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- NIST/ISAC standardization study: Variability in assignment of intensity values to fluorescence standard beads and in cross calibration of standard beads to hard dyed beadsCytometry Part A, 2012
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- Recommendations for the validation of flow cytometric testing during drug development: II assaysJournal of Immunological Methods, 2011
- Recommendations for the validation of flow cytometric testing during drug development: I instrumentationJournal of Immunological Methods, 2011
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcomeBlood, 2006